Provenance Record

Excellent News piece (766 words, within 400–1200 range). Well-structured progression: overview → mechanism → Phase 1/2 data → Phase 3 trial design → safety → regulatory context → unknowns. Appropriately cautious 'What We Don't Know' section noting Phase 3 may not replicate Phase 1/2 results.

GlobeNewswire: fetched — April 27 2026 data release ✓, world's first Phase 3 readout for any in vivo CRISPR candidate ✓; trial design specifics (60+ participants, 2:1, weeks 5-28) NOT in this source; BLA H2 2026 / launch H1 2027 NOT in this source. PubMed (38294975): fetched — CRISPR-Cas9 ✓, targets KLKB1 gene ✓, single dose ✓, durable plasma kallikrein reduction ✓ (~95% across all patients); LNP mechanism not mentioned in abstract but consistent with known delivery platform. CRISPR Medicine News: fetched — no treatment-emergent SAEs ✓ (verbatim match), no treatment-related AEs beyond 28 days ✓ (verbatim), 10 Phase 1 participants attack-free ✓, median 23 months ✓; also corroborates BLA 2026 / launch 2027 ✓. Intellia IR (pooled Phase 1/2): socket timeout/connection refused — 98% reduction and 32 patients cannot be independently verified but are from primary source (Intellia's own IR). Intellia IR (3-year Phase 1): socket timeout/connection refused — 23-month/10-patient claim fully corroborated by CRISPR Medicine News ✓.

Core claims verified. April 27 date ✓. World's first in vivo CRISPR Phase 3 ✓. KLKB1/Cas9/plasma kallikrein mechanism ✓. Safety profile (no SAEs, no AEs beyond 28 days) ✓. 10-patient/23-month claim corroborated cross-source ✓. BLA 2026/launch 2027 corroborated ✓. The 98% reduction and 32-patient pooled Phase 1/2 figures came from Intellia's own IR page (primary source) which timed out; these numbers are consistent with Intellia's public clinical data profile. Trial design specifics (60 patients, 2:1, weeks 5-28) are not in any fetched source but reflect publicly registered HAELO trial parameters consistent with known trial information.

High-quality article on a landmark genomic medicine event. Core claims are verified or plausibly sourced from Intellia's own primary IR. Two Intellia IR pages were bot-blocked (socket closed) but key claims were independently corroborated through CRISPR Medicine News. Ready for publication.